2. Lipids
  3. Lipids In Drug Delivery
  4. Lipid Nanoparticles
  5. LNPs & Liposomes

LNPs & Liposomes

LNPs & Liposomes (41):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-153229
    Firefly luciferase mRNA-LNP
    Firefly luciferase mRNA-LNP is a lipid nanoparticle (LNP) containing firefly luciferase mRNA. Firefly luciferase mRNA-LNP exhibits a stable nanostructure, in which LNP plays a key role in effectively protecting and transporting mRNA to cells. Luciferase is a bioluminescent reporter gene for gene regulation and functional studies. Firefly Luciferase mRNA-LNP expresses firefly luciferase protein after entering the cells, which is often used for promoter activity detection or dual fluorescent molecular complementation experiments. Firefly luciferase mRNA-LNP is studied in research for RNA delivery, cell viability, and translation efficiency.
    Firefly luciferase mRNA-LNP
  • HY-153231A
    eGFP mRNA-LNP (500 ng/μL)
    eGFP mRNA-LNP (500 ng/μL) is a lipid nanoparticle (LNP) containing eGFP mRNA. eGFP mRNA-LNP carries Enhanced Green Fluorescent Protein (eGFP), which will express green fluorescent protein after entering the cell. eGFP is commonly used as a reporter gene detectable by fluorescence microscopy or flow cytometry (excitation wavelength = 488 nm; emission wavelength = 535/40 bandpass). eGFP mRNA-LNP can be used for RNA delivery, translation efficiency and cell viability.
    eGFP mRNA-LNP (500 ng/μL)
  • HY-153235
    COVID-19 Spike Protein mRNA-LNP
    COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) containing mRNA encoding COVID-19 Spike Protein. COVID-19 Spike Protein undertakes the functions of virus binding with host cell receptors, thereby mediating the entry of COVID-19 virus into cells. COVID-19 Spike Protein is an important site of action for host neutralizing antibodies and a key target for vaccine design. COVID-19 Spike Protein mRNA-LNP can be used for RNA delivery, vaccine formulation and design targeting SARS-CoV-2.
    COVID-19 Spike Protein mRNA-LNP
  • HY-153232
    eGFP circRNA-LNP
    eGFP circRNA-LNP is a lipid nanoparticle (LNP) containing eGFP circRNA, suitable for assays of RNA delivery, translation efficiency, cell viability, etc. eGFP circRNA carries Enhanced Green Fluorescent Protein (Enhanced Green Fluorescent Protein) eGFP, which will express green fluorescent protein after entering the cell. eGFP is commonly used as a reporter gene detectable by fluorescence microscopy or flow cytometry.
    eGFP circRNA-LNP
  • HY-177846
    Liposomal Melatonin
    Liposomal Melatonin is a specialized delivery system that encapsulates melatonin within tiny liposomes. These liposomes act as protective shells, enhancing the absorption and bioavailability of melatonin. Melatonin is an antioxidant, anti-inflammatory, fr
    Liposomal Melatonin
  • HY-185373
    Paclitaxel liposome
    Paclitaxel liposome is a liposome-encapsulated form of Paclitaxel (HY-B0015). Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel liposome is characterized by reduced acute toxicity, prolonged circulating half-life of paclitaxel, and enhanced accumulation at tumor sites. Paclitaxel liposome can be used in research related to breast cancer and locally advanced esophageal squamous cell carcinoma.
    Paclitaxel liposome
  • HY-185370
    Doxorubicin liposome
    Doxorubicin liposome is a liposome-encapsulated form of doxorubicin hydrochloride (HY-15142). Doxorubicin hydrochloride, a cytotoxic anthracycline antibiotic, is a potent human DNA topoisomerase I and topoisomerase II inhibitor. Compared to traditional doxorubicin, liposome encapsulation reduces its cardiotoxicity and prolongs its circulation time, thus enabling it to effectively target tumor tissue.
    Doxorubicin liposome
  • HY-185399
    Vincristine sulfate liposome
    Vincristine sulfate liposome is?a liposome-encapsulated form of Vincristine sulfate (HY-N0488), an antitumor vinca alkaloid. Vincristine sulfate liposome can prolong the drug's circulation time in the body and release the drug slowly at the tumor blood vessels.
    Vincristine sulfate liposome
  • HY-177840
    Liposomal Curcumin
    Liposomal Curcumin is a specialized delivery system that encapsulates curcumin within tiny liposomes. These liposomes act as protective shells, enhancing the absorption and bioavailability of curcumin. Curcumin is a polyphenol compound extracted from the
    Liposomal Curcumin
  • HY-177829
    Liposomal Vitamin C
    Liposomal Vitamin C is a specialized delivery system that encapsulates vitamin C within tiny liposomes. These liposomes act as protective shells, enhancing the absorption and bioavailability of vitamin C. Vitamin C (L-ascorbic acid) is a water-soluble vit
    Liposomal Vitamin C
  • HY-177843
    Liposomal NMN
    Liposomal NMN is a specialized delivery system that encapsulates NMN within tiny liposomes. These liposomes act as protective shells, enhancing the absorption and bioavailability of NMN. NMN (β-Nicotinamide Mononucleotide) is a naturally occurring key met
    Liposomal NMN
  • HY-177839
    Liposomal Coenzyme Q10 98%
    Liposomal Coenzyme Q10 is a specialized delivery system that encapsulates coenzyme Q10 within tiny liposomes. These liposomes act as protective shells, enhancing the absorption and bioavailability of coenzyme Q10. Coenzyme Q10 (CoQ10), also called ubiquin
    Liposomal Coenzyme Q10
  • HY-185398
    Amikacin liposome
    Amikacin liposome is a liposome-encapsulated form of Amikacin disulfate (HY-B0509B), an aminoglycoside antibiotic with antibactericidal avtivity. Amikacin liposome prolongs the release of amikacin in the lungs and reduces systemic exposure, thereby lowering systemic toxicity.
    Amikacin liposome
  • HY-185371
    Irinotecan liposome
    Irinotecan liposome is a liposome-encapsulated form of Irinotecan hydrochlorid (HY-16562A) (a topoisomerase I inhibitor). Compared with Irinotecan, Irinotecan liposome enhances antitumor activity, reduces drug release rate, and avoids neutropenia.
    Irinotecan liposome
  • HY-185389
    Cisplatin liposome
    Cisplatin liposome is a liposome-encapsulated form of Cisplatin (HY-17394). Cisplatin (CDDP) is an anti-tumor chemotherapeutic agent that cross-links with DNA, causing DNA damage in cancer cells. Cisplatin liposome prolongs drug circulation time and slowly releases the drug, allowing it to accumulate in the tumor and exert its killing effect.
    Cisplatin liposome
  • HY-185388
    Bupivacaine liposome
    Bupivacaine liposome is a liposome-encapsulated form of Bupivacaine (HY-B0405). Bupivacaine is an NMDA receptor inhibitor. During the action potential, Bupivacaine blocks sodium channels, thereby inhibiting the generation and conduction of nerve impulses induced by painful stimuli. Bupivacaine liposome reduces the release rate of Bupivacaine, thus achieving a long-lasting pain relief effect.
    Bupivacaine liposome
  • HY-185372
    Mitoxantrone hydrochloride liposome
    Mitoxantrone hydrochloride liposome is a liposome-encapsulated Mitoxantrone hydrochloride (HY-13502A) (a topoisomerase II inhibitor). Compared to regular Mitoxantrone hydrochloride, Mitoxantrone hydrochloride liposome enhances antitumor activity and prolongs drug circulation time in the body.
    Mitoxantrone hydrochloride liposome
  • HY-185390
    Verteporfin liposome
    Verteporfin liposome is a liposome-encapsulated form of Verteporfin (HY-B0146). Verteporfin is a photosensitizer used in photodynamic therapy to eliminate abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin liposome prolongs drug circulation time and provides slow release, allowing the drug to accumulate in newly formed blood vessels.
    Verteporfin liposome
  • HY-160952
    Cytarabine-daunorubicin 1256639-86-7
    Cytarabine-daunorubicin (CPX 351) is a Liposomal formulation prepared from Cytarabine (HY-13605) and Daunorubicin (HY-13062A) at a fixed synergistic molar ratio of 5:1. Cytarabine-daunorubicin improves secondary acute myeloid leukemia. Cytarabine-daunorubicin can be used in research related to secondary acute myeloid leukemia, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia.
    Cytarabine-daunorubicin
  • HY-177849
    Liposomal Amphotericin B
    Liposomal Amphotericin B is a liposome-encapsulated form of Amphotericin B (HY-B0221). Amphotericin B is a polyene antifungal agent against a wide variety of fungal pathogens. Amphotericin B binds irreversibly to ergosterol, resulting in disruption of membrane integrity and ultimately cell death. Liposomal Amphotericin B can significantly reduce the toxicity of Amphotericin B.
    Liposomal Amphotericin B